SCHEMBL205989

SCHEMBL205989

Cc1cc(O)c(F)c(C)c1Br

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 3/20 0.36
HPGD P15428 2/20 0.36
MAPK1 P28482 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
G6PD P11413 1/20 0.36
CYP2C9 P11712 1/20 0.36
PKM P14618 1/20 0.36
ALOX15 P16050 1/20 0.36
ALOX12 P18054 1/20 0.36
CYP2C19 P33261 1/20 0.36
CCR6 P51684 1/20 0.36
HIF1A Q16665 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
AKT1 P31749 1/20 0.36
ESR2 Q92731 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31089300 0.82 ALDH1A1 (0.36) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL658795 0.78 ACHE (0.43) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL23249000 0.78 CYP3A4 (0.32) MAPK1CYP1A2CYP3A4
SCHEMBL29863478 0.78 CYP3A4 (0.32) MAPK1CYP1A2CYP3A4
SCHEMBL5852636 0.76 KDM1A (0.34)
SCHEMBL31088800 0.74 PTGS1 (0.38) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL24724647 0.74 PTGS1 (0.38) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL2471296 0.73 ACHE (0.43) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL9670626 0.73 ACHE (0.43) MAPTALDH1A1KDM4EHPGDMAPK1
SCHEMBL8755669 0.73 MAPT (0.36) MAPTALDH1A1KDM4EHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466781-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
US-20230048992-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-02-16 US disclosed
US-20230048992-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-02-16 US disclosed
CN-115279359-A Novel thyromimetic agents 速通医疗公司 2022-11-01 CN disclosed
EP-4065098-A1 NOVEL THYROMIMETICS Autobahn Therapeutics, Inc. (US) 2022-10-05 EP disclosed
WO-2021108549-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-06-03 WO disclosed
WO-2021108549-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-06-03 WO disclosed
CN-104870429-A Benzofuran derivative, preparation method therefor, and medical application thereof SICHUAN HAISCO PHARMACEUTICAL CO LTD 2015-08-26 CN disclosed
US-8791266-B2 Thyroid hormone β receptor agonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-07-29 US disclosed
US-8791266-B2 Thyroid hormone β receptor agonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-07-29 US disclosed
US-20100197761-A1 Fused cyclic compounds YASUMA TSUNEO 2010-08-05 US disclosed
US-7732626-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-08 US disclosed
US-7732626-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-08 US disclosed
US-7732626-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-08 US disclosed
US-20100004312-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
US-20100004312-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
US-20100004312-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
CN-101616913-A Fused ring compound TAKEDA PHARMACEUTICAL 2009-12-30 CN disclosed
EP-2041123-A2 FUSED CYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2009-04-01 EP disclosed
WO-2008001931-A2 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230048992-A1 NOVEL THYROMIMETICS TSHR, TPO, CHRM1 MAPT 1197/4885ALDH1A1 1048/4885KDM4E 4151/4885
US-12466781-B2 Thyromimetics TPO, TSHR, CHRM1 MAPT 1111/4885ALDH1A1 1070/4885KDM4E 4352/4885
US-20100004312-A1 FUSED CYCLIC COMPOUNDS GPR119, GLP1R, GPR65 MAPT 4546/4885ALDH1A1 3122/4885KDM4E 3536/4885
US-20100197761-A1 Fused cyclic compounds GPR119, GLP1R, GPR65 MAPT 4546/4885ALDH1A1 3122/4885KDM4E 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.